Ultragenyx Pharmaceutical Company Profile (NASDAQ:RARE)

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical logoUltragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RARE
  • CUSIP:
Key Metrics:
  • Previous Close: $65.02
  • 50 Day Moving Average: $61.04
  • 200 Day Moving Average: $62.16
  • 52-Week Range: $46.52 - $133.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.71
  • P/E Growth: -0.43
  • Market Cap: $2.66B
  • Outstanding Shares: 39,435,000
  • Beta: 1.53
Additional Links:
Companies Related to Ultragenyx Pharmaceutical:

Analyst Ratings

Consensus Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) (?)
Ratings Breakdown: 2 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $97.29 (45.62% upside)

Analysts' Ratings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Show:
DateFirmActionRatingPrice TargetDetails
8/25/2016Leerink SwannReiterated RatingBuy$86.00View Rating Details
8/9/2016Cowen and CompanyReiterated RatingBuyView Rating Details
8/8/2016JPMorgan Chase & Co.Set Price TargetBuy$110.00View Rating Details
8/9/2016Piper Jaffray Cos.Set Price TargetBuy$70.00 -> $82.00View Rating Details
8/9/2016Credit Suisse Group AGReiterated RatingBuy$101.00View Rating Details
8/9/2016WedbushReiterated RatingOutperform$92.00View Rating Details
8/1/2016Jefferies GroupSet Price TargetBuy$109.00View Rating Details
7/18/2016Robert W. BairdReiterated RatingOutperform$85.00View Rating Details
7/15/2016Canaccord GenuityReiterated RatingBuy$120.00View Rating Details
6/28/2016Bank of America Corp.Initiated CoverageBuy$72.00View Rating Details
6/8/2016Morgan StanleyReiterated RatingHoldView Rating Details
6/8/2016JMP SecuritiesReiterated RatingBuy$80.00 -> $84.00View Rating Details
2/28/2016HC WainwrightReiterated RatingBuy$104.00View Rating Details
2/19/2016Citigroup Inc.Lower Price Target$88.00 -> $67.00View Rating Details
2/9/2016Sterne Agee CRTInitiated CoverageBuyView Rating Details
12/1/2015Stifel NicolausInitiated CoverageBuy -> Buy$125.00 -> $125.00View Rating Details
8/31/2015Raymond James Financial Inc.Initiated CoverageOutperform$125.00View Rating Details
7/13/2015SunTrust Banks Inc.Boost Price TargetBuy$82.00 -> $119.00View Rating Details
3/30/2015MLV & Co.Initiated CoverageBuy$79.00View Rating Details
3/24/2015CRT CapitalInitiated CoverageBuy$90.00View Rating Details
(Data available from 8/30/2014 forward)

Earnings

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/8/2016Q2($1.44)($1.46)ViewN/AView Earnings Details
5/9/2016Q1($1.29)($1.35)ViewN/AView Earnings Details
2/25/2016Q4($1.14)($1.42)ViewListenView Earnings Details
11/9/2015Q3($0.87)($1.03)ViewN/AView Earnings Details
8/13/2015Q215($0.63)($0.83)ViewListenView Earnings Details
5/11/2015Q1 15($0.54)($0.63)ViewListenView Earnings Details
3/25/2015Q414($0.53)($0.52)ViewListenView Earnings Details
11/10/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014Q214($0.42)($0.45)ViewN/AView Earnings Details
5/12/2014Q114($0.37)($0.85)ViewN/AView Earnings Details
3/24/2014($0.38)($4.98)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Current Year EPS Consensus Estimate: $-5.93 EPS
Next Year EPS Consensus Estimate: $-6.24 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.38)($1.13)($1.26)
Q2 20164($1.59)($1.13)($1.39)
Q3 20164($1.55)($1.51)($1.53)
Q4 20164($1.66)($1.54)($1.60)
Q1 20171($1.70)($1.70)($1.70)
Q2 20171($1.73)($1.73)($1.73)
Q3 20171($1.67)($1.67)($1.67)
Q4 20171($1.65)($1.65)($1.65)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016Emil D KakkisCEOSell20,000$67.61$1,352,200.00View SEC Filing  
7/21/2016Sunil AgarwalInsiderSell649$52.68$34,189.32View SEC Filing  
7/15/2016Emil D KakkisCEOSell20,000$50.85$1,017,000.00View SEC Filing  
6/20/2016Sunil AgarwalInsiderSell650$54.16$35,204.00View SEC Filing  
5/24/2016Sunil AgarwalInsiderSell650$66.00$42,900.00View SEC Filing  
5/16/2016Emil D KakkisCEOSell20,000$59.95$1,199,000.00View SEC Filing  
4/20/2016Sunil AgarwalInsiderSell649$70.53$45,773.97View SEC Filing  
4/15/2016Emil D KakkisCEOSell20,000$70.33$1,406,600.00View SEC Filing  
3/22/2016Sunil AgarwalInsiderSell650$61.45$39,942.50View SEC Filing  
2/22/2016Sunil AgarwalInsiderSell658$63.48$41,769.84View SEC Filing  
1/20/2016Sunil AgarwalinsiderSell585$72.83$42,605.55View SEC Filing  
12/31/2015Emil D. KakkisCEOSell20,000$114.52$2,290,400.00View SEC Filing  
12/22/2015Sunil AgarwalInsiderSell498$114.81$57,175.38View SEC Filing  
12/18/2015Theodore Alan HuizengainsiderSell1,500$110.55$165,825.00View SEC Filing  
8/20/2015Sunil AgarwalinsiderSell17,020$111.18$1,892,283.60View SEC Filing  
8/12/2015Thomas Richard KassbergSVPSell3,334$109.70$365,739.80View SEC Filing  
7/20/2015Shalini SharpCFOSell3,854$131.95$508,535.30View SEC Filing  
7/8/2015Thomas Richard KassbergSVPSell3,334$102.12$340,468.08View SEC Filing  
6/18/2015Shalini SharpCFOSell4,000$96.08$384,320.00View SEC Filing  
6/17/2015Theodore Alan HuizengaInsiderSell1,500$94.80$142,200.00View SEC Filing  
6/10/2015Thomas Richard KassbergSVPSell3,334$88.19$294,025.46View SEC Filing  
4/20/2015Shalini SharpCFOSell4,000$62.23$248,920.00View SEC Filing  
4/8/2015Thomas Richard KassbergSVPSell3,333$58.02$193,380.66View SEC Filing  
1/20/2015Shalini SharpCFOSell4,000$51.24$204,960.00View SEC Filing  
12/18/2014Shalini SharpCFOSell4,000$44.82$179,280.00View SEC Filing  
12/10/2014Thomas Richard KassbergSVPSell3,333$40.22$134,053.26View SEC Filing  
12/4/2014William AliskiDirectorSell6,000$42.16$252,960.00View SEC Filing  
11/20/2014Shalini SharpCFOSell4,000$44.07$176,280.00View SEC Filing  
11/12/2014Thomas Richard KassbergSVPSell3,333$41.85$139,486.05View SEC Filing  
10/8/2014Thomas Richard KassbergSVPSell3,333$53.26$177,515.58View SEC Filing  
9/18/2014Shalini SharpCFOSell4,000$56.00$224,000.00View SEC Filing  
9/10/2014Thomas Richard KassbergSVPSell3,333$54.82$182,715.06View SEC Filing  
9/3/2014Thomas Richard KassbergSVPSell20,000$53.91$1,078,200.00View SEC Filing  
8/18/2014Shalini SharpCFOSell4,000$53.97$215,880.00View SEC Filing  
7/14/2014Group Holdings (Sbs) Advis TpgInsiderSell488,820$37.60$18,379,632.00View SEC Filing  
1/31/2014Fmr LlcInsiderBuy175,000$21.00$3,675,000.00View SEC Filing  
1/30/2014Shalini SharpCFOBuy4,500$21.00$94,500.00View SEC Filing  
1/30/2014Thomas Richard KassbergSVPBuy1,500$21.00$31,500.00View SEC Filing  
1/30/2014William AliskiDirectorBuy5,000$21.00$105,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ultragenyx Pharmaceutical (NASDAQ:RARE)
DateHeadline
live-pr.com logoUltragenyx Pharmaceutical Inc. (RARE) - Financial and Strategic SWOT Analysis Review - New Report Available (NASDAQ:RARE)
www.live-pr.com - August 24 at 10:04 AM
streetinsider.com logoUltragenyx Pharma (RARE) Announces Presentations Highlighting KRN23 at ASBMR Meeting (NASDAQ:RARE)
www.streetinsider.com - August 23 at 11:32 AM
publicnow.com logoUltragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting (NASDAQ:RARE)
www.publicnow.com - August 23 at 11:32 AM
stocksdaily.net logoCan Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Meet Analysts Expectations? - Stocks Daily (NASDAQ:RARE)
www.stocksdaily.net - August 20 at 6:40 PM
finance.yahoo.com logoULTRAGENYX PHARMACEUTICAL INC. Financials (NASDAQ:RARE)
finance.yahoo.com - August 17 at 7:23 PM
News IconUltragenyx Pharmaceutical Inc (NASDAQ:RARE): We Bought The Stock At $57.40, Now Up Crazy 20% Quickly (NASDAQ:RARE)
www.marketnewscall.com - August 12 at 10:14 AM
News IconUltragenyx Pharmaceutical Inc (NASDAQ:RARE): We Bought The Stock At $57.40, Now Up Crazy 20% Quickly - Market News Call (NASDAQ:RARE)
www.marketnewscall.com - August 11 at 7:34 PM
tradecalls.org logoUltragenyx Pharmaceutical (RARE) Shares are Up 4.93% - Trade Calls (NASDAQ:RARE)
www.tradecalls.org - August 9 at 7:20 PM
publicnow.com logoUltragenyx to Present at Upcoming Investor Conferences (NASDAQ:RARE)
www.publicnow.com - August 9 at 10:15 AM
rttnews.com logoEARNINGS SUMMARY: Details of Ultragenyx Pharmaceutical Inc Q2 Earnings Report (NASDAQ:RARE)
www.rttnews.com - August 8 at 7:18 PM
globenewswire.com logoUltragenyx Reports Second Quarter 2016 Financial Results and Corporate Update (NASDAQ:RARE)
globenewswire.com - August 8 at 7:18 PM
twst.com logoUltragenyx Pharmaceutical Inc.: Ultragenyx Reports Second Quarter 2016 Financial Results and Corporate Update (NASDAQ:RARE)
www.twst.com - August 8 at 7:18 PM
4-traders.com logoUltragenyx Pharmaceutical : reports 2Q loss (NASDAQ:RARE)
www.4-traders.com - August 8 at 7:18 PM
sg.finance.yahoo.com logoUltragenyx reports 2Q loss (NASDAQ:RARE)
sg.finance.yahoo.com - August 8 at 7:18 PM
biz.yahoo.com logoQ2 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close (NASDAQ:RARE)
biz.yahoo.com - August 8 at 11:47 AM
News IconUltragenyx Pharmaceutical Inc (NASDAQ:RARE): That’s How Our Subscribers Are Up 13% In One Week (NASDAQ:RARE)
www.marketnewscall.com - August 4 at 10:12 AM
biz.yahoo.com logoULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events (NASDAQ:RARE)
biz.yahoo.com - August 3 at 7:23 PM
twst.com logoUltragenyx Pharmaceutical Inc.: Ultragenyx to Host Conference Call for Second Quarter 2016 Financial Results and Corporate Update (NASDAQ:RARE)
www.twst.com - August 1 at 6:49 PM
insidermonkey.com logoHere’s What We’re Looking For From Ultragenyx Pharmaceutical Inc (RARE) (NASDAQ:RARE)
www.insidermonkey.com - August 1 at 6:49 PM
publicnow.com logoUltragenyx to Host Conference Call for Second Quarter 2016 Financial Results and Corporate Update (NASDAQ:RARE)
www.publicnow.com - August 1 at 8:41 AM
marketexclusive.com logoHere’s What We’re Looking For From Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) (NASDAQ:RARE)
marketexclusive.com - July 30 at 9:52 AM
marketexclusive.com logoHere's What We're Looking For From Ultragenyx Pharmaceutical Inc ... - Market Exclusive (NASDAQ:RARE)
marketexclusive.com - July 29 at 7:13 PM
equities.com logoUltragenyx Pharmaceutical Inc (RARE) Jumps 7.41% on July 27 - Equities.com (NASDAQ:RARE)
www.equities.com - July 29 at 10:04 AM
streetinsider.com logoUltragenyx Pharma (RARE) Completes Ace-ER Phase 3 Enrollment as GNE Myopathy Treatment - StreetInsider.com (NASDAQ:RARE)
www.streetinsider.com - July 29 at 10:04 AM
publicnow.com logoUltragenyx Announces Completion of Enrollment in Phase 3 Study of KRN23 in Adults with X-Linked Hypophosphatemia (XLH) (NASDAQ:RARE)
www.publicnow.com - July 28 at 8:58 AM
4-traders.com logoUltragenyx Pharmaceutical : Commit To Buy Ultragenyx Pharmaceutical At $40, Earn 12% Annualized Using Options (NASDAQ:RARE)
www.4-traders.com - July 27 at 7:26 PM
News IconUltragenyx Pharmaceutical jumps 5.48% on July 26 (NASDAQ:RARE)
www.thepharmaletter.com - July 27 at 10:05 AM
nasdaq.com logoCommit To Buy Ultragenyx Pharmaceutical At $40, Earn 12% Annualized Using Options (NASDAQ:RARE)
www.nasdaq.com - July 27 at 10:05 AM
publicnow.com logoUltragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy (NASDAQ:RARE)
www.publicnow.com - July 27 at 8:38 AM
tradecalls.org logoUltragenyx Pharmaceutical (RARE) Shares are Up 1.05% - Trade Calls (NASDAQ:RARE)
www.tradecalls.org - July 25 at 7:10 PM
fidaily.com logoInsider Trading Activity - Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Finance Daily (NASDAQ:RARE)
www.fidaily.com - July 21 at 7:23 PM
News IconUltragenyx Pharmaceutical Inc. (NASDAQ:RARE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:RARE)
www.engelwooddaily.com - July 21 at 9:55 AM
equities.com logoUltragenyx Pharmaceutical Inc (RARE) Drops 5.57% on July 19 - Equities.com (NASDAQ:RARE)
www.equities.com - July 21 at 9:55 AM
News IconHot Biotech Stocks Recap: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - The Voice Registrar (NASDAQ:RARE)
voiceregistrar.com - July 19 at 8:01 AM
News IconUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Wall Street Analyst Recommendation Outlook - TGP (NASDAQ:RARE)
telanaganapress.com - July 18 at 12:32 PM
News IconPerformance watch list: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - News Oracle (NASDAQ:RARE)
www.newsoracle.com - July 18 at 12:32 PM
benzinga.com logoUltragenyx's Final Stage Study Of Recombinant Human Beta-Glucuronidase Meets Primary Endpoint (NASDAQ:RARE)
www.benzinga.com - July 15 at 12:11 PM
rttnews.com logoUltragenyx Pharmaceutical Inc. (RARE) Is Rising On Phase 3 Study Results (NASDAQ:RARE)
www.rttnews.com - July 15 at 12:11 PM
marketexclusive.com logoUnderstanding The Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Data Dump (NASDAQ:RARE)
marketexclusive.com - July 15 at 12:11 PM
News IconEye on Stock Volatility for: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Engelwood Daily (NASDAQ:RARE)
www.engelwooddaily.com - July 14 at 7:16 PM
streetinsider.com logoUltragenyx Pharma (RARE) Announces rhGUS Phase 3 Met Primary Endpoint in Sly Syndrome - StreetInsider.com (NASDAQ:RARE)
www.streetinsider.com - July 14 at 7:16 PM
biz.yahoo.com logoULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:RARE)
biz.yahoo.com - July 14 at 5:11 PM
marketwatch.com logoUltragenyx shares rise on metabolic drug study results (NASDAQ:RARE)
www.marketwatch.com - July 14 at 4:34 PM
publicnow.com logoUltragenyx Announces Positive Topline Data from Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7 (NASDAQ:RARE)
www.publicnow.com - July 14 at 4:18 PM
investorplace.com logo3 Stocks to Watch on Thursday: Monsanto Company (MON), Ultragenyx Pharmaceutical Inc (RARE) and Yum! Brands ... - Investorplace.com (NASDAQ:RARE)
investorplace.com - July 14 at 10:39 AM
investorplace.com logo3 Stocks to Watch on Thursday: Monsanto Company (MON), Ultragenyx Pharmaceutical Inc (RARE) and Yum! Brands, Inc. (YUM) (NASDAQ:RARE)
investorplace.com - July 14 at 9:45 AM
streetinsider.com logoUltragenyx Pharma (RARE) to Present Phase 3 Data for rhGUS in MPS 7 at MPS Symposium - StreetInsider.com (NASDAQ:RARE)
www.streetinsider.com - July 13 at 7:26 PM
publicnow.com logoUltragenyx to Present Phase 3 Data for Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7 (MPS 7) at 14th International Symposium on MPS and Related Diseases (NASDAQ:RARE)
www.publicnow.com - July 13 at 4:38 PM
finance.yahoo.com logo4:18 pm Ultragenyx Pharma announces that data from the Phase 3 study of recombinant human beta-glucuronidase will be presented at the 14th International Symposium on MPS and Related Diseases, taking place July 14-17 in Bonn, Germany (NASDAQ:RARE)
finance.yahoo.com - July 13 at 4:18 PM
News IconUltragenyx Pharmaceutical Inc Draws Bearish Attention After Forming Double Bottom Pattern - Consumer Eagle (NASDAQ:RARE)
www.consumereagle.com - July 12 at 7:18 PM

Social

Ultragenyx Pharmaceutical (NASDAQ:RARE) Chart for Tuesday, August, 30, 2016


Last Updated on 8/30/2016 by MarketBeat.com Staff